Suvoda Introduces Extensible Software Platform Bringing Proven Tech Innovation to Clinical Trial Management
PR99531
PHILADELPHIA, Feb. 7, 2023 /PRNewswire=KYODO JBN/ --
-- Platform reduces friction across the eConsent, IRT, and eCOA user
experience for sponsors, CROs, sites and patients.
Suvoda LLC (
) , a global clinical trial technology company that specializes in complex
studies in therapeutic areas like oncology, central nervous system (CNS), and
rare disease, today unveiled a purpose-built software platform designed
specifically to provide drug trial sponsors and sites a seamless way to manage
complex, mission-critical, and time-sensitive moments on the patient journey.
Click to tweet (
) .
Logo - https://mma.prnewswire.com/media/1759317/Suvoda_Logo.jpg
Drawing on more than a decade of expertise following the launch of its
innovative IRT solution, and having supported more than 1,000 trials across 80
countries, Suvoda introduces a low-code/no-code platform to the eClinical
market unifying its eConsent, IRT, and eCOA solutions. Designed to address real
challenges facing clinical trials, the Suvoda Platform minimizes friction
across the user experience, while reducing and simplifying integrations, and
strengthening data governance, so studies can be implemented more efficiently
and with less risk of downtime.
"Clinical trials are increasingly complex, expensive, and fraught with
challenges that are affecting trial execution – mid-study changes, data silos,
trial delays, and more," said Jagath Wanninayake, CEO of Suvoda. "To meet these
challenges, our team organically built a platform upon which we are delivering
the next generation of clinical trial applications designed to handle
complexity with ease, and reduce overall risk throughout trials. Our goal is
always for sponsors and site users to spend less time with technology and more
time on what is most important to them…uncovering scientific breakthroughs and
focusing on the patients we all ultimately serve."
The Suvoda Platform enables Suvoda's IRT, eConsent, and eCOA solutions to work
seamlessly together and harmoniously with other applications, to be easily
tailored to meet the needs of each protocol, and to be upgradable to benefit
from continuous enhancements. The Suvoda Platform provides a number of
benefits, including:
Enhanced user experience and reduced workload. The new platform enables single
sign-on and provides a consistent interface across Suvoda's eConsent, IRT, and
eCOA solutions, with smooth user workflows that allow clinicians to move
seamlessly from one task to the next. This reduces workload and training so
sites can focus more of their time on research and patients.
Rapid design and deployment of complex trials. The platform's low-code/no-code
technology streamlines study start-up and mid-study changes, even for the most
complex trials, while advanced design tools make customizations more practical
and sponsor standards easier to implement. A harmonized deployment process
across three solutions saves study teams time and effort.
Improved data workflow and reduced integrations. Suvoda's unified platform
enables all patient and site data across eConsent, IRT, and eCOA to be
centrally collected, managed, analyzed, and stored. This is expected to result
in better data governance for sponsors, provide sites access to real-time
information, and deliver a more robust eClinical ecosystem. In addition,
customers benefit from three already-integrated solutions–eConsent, IRT and
eCOA–while the platform's comprehensive API surface simplifies other necessary
integrations with third-party solutions and sponsor systems.
Future-proofed eClinical programs. Users of the platform will always have the
latest trial technology with Suvoda because upgrades can be made throughout the
life of the trial without losing customizations. In addition, with release
opt-in, customers can choose which updates to accept, giving them control of
their internal validation, acceptance, and training processes. Finally, Suvoda
makes implementing enterprise standards future-proof by allowing sponsors to
upgrade while maintaining their proprietary processes and standards across all
products built on the Suvoda Platform.
"Whether it's sponsors, CROs, site teams, or patients, users expect a seamless
trial experience digitally and in-person, so we've designed the new platform to
deliver that," said Andrew McVeigh, chief architect at Suvoda. "Suvoda offers a
powerful trial management platform that feels like a consumer app because we've
put the user at the center of our design. Our robust back-end and intuitive
design puts greater control into our customers' hands and delivers the power to
manage trials of any level of complexity."
Click here (
) for more information on the Suvoda Platform.
About Suvoda
Suvoda is a global clinical trial technology company specializing in complex,
life-sustaining studies in therapeutic areas like oncology, central nervous
system (CNS), and rare disease. Founded in 2013 by experts in eClinical
technologies, Suvoda empowers clinical trial professionals to manage the most
urgent moments in the most urgent trials through advanced software solutions
delivered on a single platform. Headquartered outside Philadelphia, Suvoda also
maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania, and
Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) of
close to 70, far exceeding the technology industry average of 50, and has been
selected by trial sponsors and CROs to support more than 1,000 trials across 80
countries. To learn more, visit suvoda.com. Follow Suvoda on Twitter (
) and LinkedIn (
) .
For information contact:
Mara Conklin, (847) 340-6823
mconklin@teamclarus.com
Kathy Zoeller, (312) 485-2422
kathy@mattsonpr.com
Source - Suvoda LLC
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
